SUPERFIBRONECTIN--A NEW ANTIMETASTATIC AGENT

描述：肿瘤发生和转移依赖于一个复杂的系列 据信，细胞附着在细胞生长过程中起着关键作用， 在这些过程中。 申请人已经开发了聚合物形式的 细胞粘附分子纤连蛋白， 称为超纤连蛋白（sFN），也抑制细胞附着， 体外细胞迁移。 在体内，sFN具有抗转移活性 针对接种在免疫缺陷小鼠中的几种人类肿瘤。 对卵巢癌细胞系的初步研究表明， sFN能抑制肿瘤的生长和腹膜内扩散 细胞 sFN没有明显的毒性作用 治疗 申请人建议：1）测试，作为初始步骤 为了设计临床试验，sFN在糖尿病患者中的治疗效果 卵巢癌动物模型，模仿人类疾病。 2)评估 sFN毒性重点关注多器官的组织学分析 来自用递增剂量的聚合物处理的动物，和3） 开发光散射测试，以标准化sFN的生产 聚合物的 这些研究可望提供所需的资料 在第二阶段之后， 格兰特. 拟议的商业应用：不可用。

DESCRIPTION: Tumorigenesis and metastasis depend upon a complex series of events, and it is believed that cell attachment plays a critical role in those processes. The applicants have developed a polymeric form of the cell adhesion molecule fibronectin and have shown that this agent, referred to as superfibronectin (sFN), inhibits cell attachment, as well as cell migration in vitro. In vivo, sFN has anti-metastatic activity towards several human tumors inoculated in immunodeficient mice. Preliminary studies with ovarian carcinoma cell lines have shown that sFN can restrict the growth and the peritoneal spread of injected tumor cells. There have been no discernible toxic effects from the sFN treatment. The applicants propose to: 1) test , as an initial step toward designing clinical trials, the therapeutic effect of sFN in an ovarian cancer animal model that mimics the human disease. 2) to assess sFN toxicity focusing on the histological analysis of multiple organs from animals treated with escalating doses of the polymer and 3) to develop a light scattering test to standardize the production of the sFN polymer. These studies are expected to provide the information needed to proceed into experimental clinical trials after the phase II of this grant. PROPOSED COMMERCIAL APPLICATION: Not available.